Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1995-06-07
2000-05-16
Tsang, Cecilia
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 8, 514 21, 514921, A61K 3800
Patent
active
060637641
ABSTRACT:
A method for prophylactically or therapeutically treating sepsis or septic shock is described, wherein an inhibitor to tissue factor is administered to septic patients. Additionally, a method for treating inflammation is described wherein the inhibitor is administered to pateints. This inhibitor is termed lipoprotein associated coagulation inhibitor, or commonly LACI. It is 38 kD and has 276 amino acids. LACI has now been shown to be useful for the treatment of sepsis, septic shock and inflammation.
REFERENCES:
patent: 4179337 (1979-12-01), Davis et al.
patent: 4399216 (1983-08-01), Axel et al.
patent: 4495285 (1985-01-01), Shimizu et al.
patent: 4511502 (1985-04-01), Builder et al.
patent: 4530787 (1985-07-01), Shaked et al.
patent: 4569790 (1986-02-01), Koths et al.
patent: 4572798 (1986-02-01), Koths et al.
patent: 4603106 (1986-07-01), Cerami et al.
patent: 4609546 (1986-09-01), Hiratani
patent: 4620948 (1986-11-01), Builder et al.
patent: 4683195 (1987-07-01), Mullis et al.
patent: 4683202 (1987-07-01), Mullis
patent: 4711845 (1987-12-01), Gelfand et al.
patent: 4748234 (1988-05-01), Dorin et al.
patent: 4766106 (1988-08-01), Katre et al.
patent: 4847201 (1989-07-01), Kawasaki et al.
patent: 4929700 (1990-05-01), Halenbeck et al.
patent: 4966852 (1990-10-01), Wun et al.
patent: 5106833 (1992-04-01), Broze et al.
patent: 5110730 (1992-05-01), Edgington et al.
patent: 5219994 (1993-06-01), Buonassisi et al.
patent: 5223427 (1993-06-01), Edgington et al.
Day et al., Blood, vol. 76, No. 8 (Oct. 15), pp. 1538-1545, 1990.
Creasey et al., J. Clin. Invest., vol. 91, Jun., pp. 2850-2860, 1993.
Ameri et al., "Expression of Tissue Factor Pathway Inhibitor by Cultured Endothelial Cells in Response to Inflammatory Mediators", Blood, 79:3219-26 (1992).
Bailey et al., "Methylmercury as a Reversible Denaturing Agent for Agarose Gel Electrophoresis", Anal. Bioch., 70:75 (1976).
Bajaj et al., "Cultured normal human hepatocytes do not synthesize lipoprotein-associated coagulation inhibitor: Evidence that endothelium is the principal site of its synthesis", PNAS (USA ), 87:8869-73 (1990).
Bajaj et al., "Inhibitor of the Factor VIIa-Tissue Factor Complex is Reduced in Patients with Disseminated Intravascular Coagulation but Not in Patients with Severe Hepatocellular Disease", J. Clin. Invest., 79:1874 (1987).
Bevilacqua et al., "Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: Characterization and comparison with the actions of interleukin 1", PNAS (USA ), 83:4533-37 (1986).
Bolivar et al., "Construction and Characterization of New Cloning Vehicles", Gene, 2:95 (1977).
Bone et al., "Definitions for Sepsis and Organ Failure and Guidelines for the Use of Innovative Therapies in Sepsis", Chest, 101:1644-1655 (1992).
Broach, "Construction of High Copy Yeast Vectors Using 2-.mu.m Circle Sequences", Meth. Enzymol., 101:307 (1983).
Broach, "Transformation in Yeast: Development of a Hybrid Cloning Vector and Isolation of the CANI Gene", Gene, 8:121 (1979).
Broze et al., "Regulation of Coagulation by a Multivalent Kunitz-Type Inhibitor" Biochemistry, 29: 7539-46 (1990).
Broze et al., "The Lipoprotein-Associated Coagulation Inhibitor That Inhibits the Factor VII-Tissue Factor Complex Also Inhibits Factor Xa: Insight Into Its Possible Mechanism of Action", Blood, 71:335-343 (1988).
Broze et al., "Isolation of the tissue factor inhibitor produced by HepG2 hepatoma cells", PNAS (USA ), 84:1886-1890 (1987).
Clarke et al., "Selection Procedure for Isolation of Centromere DNAs from Saccharomyces cerevisiae", Meth. Enzymol., 101:300 (1983).
Clewell et al., "Nature of Col E.sub.1 Plasmid Replication in Escherichia coli in the Presence of Chloramphenicol", J. Bacteriol., 110:667 (1972).
Clewell et al., "Supercoiled Circular DNA-Protein Complex in Escherichia Coli: Purification and Induced Conversion to an Open Circular DNA Form", PNAS (USA ), 62:1159 (1969).
Cohen et al., "Nonchromosomal Antibiotic Resistance in Bacteria: Genetic Transformation of Escherichia coli by R-Factor DNA", PNAS (USA ), 69:2110 (1972).
Colucci et al., "Cultured Human Endothelial Cells Generate Tissue Factor in Response to Endotoxin", J. Clin. Invest., 71:1893-96 (1983).
Corrigan, "Heparin therapy in bacterial septicemia", J. Pediatrics, 91:695 (1977).
Creasey et al., "Tissue Factor Pathway Inhibitor Reduces Mortality from Escherichia coli Septic Shock", J. Clin. Invest., 91:2850-56 (1993).
Creasey et al., "Endotoxin and Cytokine Profile in Plasma of Baboons Challenged With Lethal and Sublethal Escherichia coli", Circ. Shock, 33:84-91 (1991).
Cross et al., "Choice of Bacteria in Animal Models of Sepsis", Infect. Immun., 61:2741-47 (1993).
Day et al., "Recombinant Lipoprotein-Associated Coagulation Inhibitor Inhibits Tissue Thromboplastin-Induced Intravascular Coagulation in the Rabbit", Blood, 76:1538-1545 (1990).
Depicker et al., "Nopaline Synthase: Transcript Mapping and DNA Sequence", J. Mol. Appl. Gen. 1:561 (1982).
Expanded Antril data fails to impress investors, Biotechnology Business News, Mar. 26, 1993.
Fiers et al., "Complete nucleotide sequence of SV40 DNA", Nature, 273:113 (1978).
Fink et al., "Laboratory Models of Sepsis and Septic Shock", J. Surgical Res., 49:186-196 (1990).
Fischer et al., "Interleukin-I Receptor Blockade Improves Survival and Hemodynamic Performance in Escherichia coli Septic Shock, But Fails to Alter Host Responses to Sublethal Endotoxemia", J. Clin. Invest., 89:1551-1557 (1992).
Fitzer-Schiller, "Synergen Stock Falls Again on Delay in Marketing Application", The Reuter Business Report, Mar. 23, 1993.
Goeddel et al., "Synthesis of human fibroblast interferon by E. coli", Nucl. Acids Res., 8:4057 (1980).
Graham et al., "A New Technique for the Assay of Infectivity of Human Adenovirus 5 DNA", Virology, 52:456 (1973).
Hess et al., "Cooperation of Glycolytic Enzymes", J. Adv. Enzyme Reg., 7:149 (1968).
Hinshaw et al., "Detection of the `Hyperdynamic State` Sepsis in the Baboon during Lethal E. coli Infusion", J. Trauma, 23:361-365 (1983).
Hinshaw et al., "Survival of Primates in LD.sub.100 Septic Shock Following Therapy with Antibody to Tumor Necrosis Factor (TNF.alpha.)", Circulatory Shock, 30:279-292 (1990).
Hitzeman et al., "Isolation and Characterization of the Yeast 3-Phosphoglycerokinase Gene (PGK) by an Immunological Screening Technique", J. Biol. Chem., 255:12073 (1980).
Holland et al., "The Primary Structures of Two Yeast Enolase Genes", J. Biol. Chem., 256:1385 (1981).
Holland et al., "Isolation and Identification of Yeast Messenger Ribonucleic Acids Coding for Enolase, Glyceraldehyde-3-phosphate Dehydrogenase, and Phosphogiycerate Kinase", Biochemistry, 17:4900 (1978).
Hsiao et al., "High-frequency transformation of yeast by plasmids containing the cloned yeast ARG4 gene", PNAS (USA ) 76:3829 (1979).
Knauf et al., "Relationship of Effective Molecular Size to Systemic Clearance in Rats of Recombinant Interleukin-2 Chemically Modified with Water-Soluble Polymers", J. Biol. Chem., 263:15064 (1988).
Lyberg et al., "Cellular cooperation in endothelial cell thromboplastin synthesis", Br. J. Haematol., 53:85-95 (1983).
Matteucci et al., "Synthesis of Deoxyoligonucleotides on a Polymer Support", J. Am. Chem. Soc., 103:3185 (1981).
Martin et al., Natural History in the 1908's, Abstracat No. 317, ICAAC Meeting, Dallas (1989).
Maxam et al., "Sequencing End-Labeled DNA with Base-Specific Chemical Cleavages", Meth. Enzymol., 65:499 (1980).
Messing et al., "A system for shotgun DNA sequencing", Nucl. Acids Res., 9:309 (1981).
Muller-Berghaus, "Pathophysiologic and Biochemical Events in Disseminated Intravascular Coagulation: Dysregulation of Procoagulant and Anticoagulant Pahtways", Sem. Thromb. Haemost., 15:58-87 (1989).
Narwroth et al., "Interleukin 1 induces endothelial cell procoagulant while suppressing cell-surface anticoagulant activity", PNAS (USA ), 83:3460-64 (1986).
Nemerson, "Tissue Factor and Hemostasis", Blood, 71:1-8 (1988).
Novotny et al., "Purification and Properties of Heparin-Releasable Lipoprotein-Associated Coagulation Inhibitor", Blood
Broze George J.
Creasey Abla A.
Delacroix-Muirheid C.
Tsang Cecilia
Washington University & Chiron Corp.
LandOfFree
Method for using lipoprotein associated coagulation inhibitor to does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for using lipoprotein associated coagulation inhibitor to, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for using lipoprotein associated coagulation inhibitor to will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-258980